CliffBio
biologic

Botox

onabotulinumtoxinA

Loss of exclusivityDecember 2003projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameBotox
Active ingredientonabotulinumtoxinA
Strength200UNITS
Dosage formFor Injection
RouteInjection, Intramuscular, Intradermal, Intradetrusor
ModalityBiologic
FDA approvalDecember 1991
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Botox patent cliff — loss of exclusivity December 2003 | CliffBio